Phase II study of pazopanib in patients with von Hippel-Lindau disease.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.4516
Abstract: 4516Background: Von Hippel-Lindau disease (VHL) is an autosomal dominant inherited disorder. Affected individuals develop vascular neoplastic lesions in multiple sites including eye, brain, pancreas, adrenal and kidney. Standards of care include surveillance imaging and surgical… read more here.
Keywords: hippel lindau; lindau disease; disease; von hippel ... See more keywords
A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.11550
Abstract: 11550Background: Topotecan and pazopanib (PAZ) individually have clinical benefit in patients (pts) with sarcomas. PAZ is a multi-tyrosine kinase inhibitor and topotecan affects endothelial cells, ... read more here.
Keywords: pazopanib oral; patients metastatic; topotecan patients; oral topotecan ... See more keywords